BioSpace News Archive

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Mario Saltarelli, M.D.,

ITI’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use

First-of-its-Kind Cyclic IMS Provides Unlimited Experimental Opportunities while the Research-Grade SYNAPT XS Brings Analytical Flexibility

Tri-State Effort Touts Life Sciences Assets to Attract More Companies, Talent and Investment

The study, conducted in collaboration with the University of Michigan utilizing Epic’s CTC technology platform, is published here in the Journal of Clinical Oncology Precision Oncology.

Lantheus expands into immuno-oncology and pharmaceutical services business through the license of NanoMab’s NM-01, an anti-PD-L1 imaging biomarker, designed to evaluate tumor immune activity and potentially guide future patient selection for immuno-oncology treatment

Schrödinger today announced that Ramy Farid, Ph.D., chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. ET in New York, NY.

This program aims to help qualified companies who need assistance with cash flow while maintaining their inventories and shorten lead time.

Rensselaer Polytechnic Institute (RPI), America’s first technological research university, has found increased efficiencies in multiple critical areas after performing a complete digital transformation utilizing JAGGAER’s advanced Enterprise Reagent Manager (ERM).